"We continue to believe that it is important for GSK to be engaged in policy debates and the political process. However, we need to ensure that there is no implication whatsoever that corporate political contributions provide us with any special privileges. We do not believe they have, and in the few countries we have given contributions we have done so in full compliance of the law. As part of our overall drive to improve transparency in terms of our interactions with governments, political leaders and candidates for public office, we believe that stopping corporate political contributions is the right thing to do. Our focus is, as it always has been, on helping governments by providing them with evidence that our medicines and vaccines provide a strong value proposition," said Andrew Witty, CEO, GlaxoSmithKline.
In the US, the company will continue to support a voluntary and independent Political Action Committee (PAC) to facilitate political contributions by eligible GSK employees.
GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com.